查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438154

2030年反义疗法/RNAi疗法市场预测：按给药途径、适应症、技术、应用和地区进行全球分析

Antisense & RNAi Therapeutics Market Forecasts to 2030 - Global Analysis By Route of Administration, Indication, Technology, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，到 2023 年，全球反义/RNAi 疗法市场规模将达到 16.6 亿美元，预计在预测期内将以 13.0% 的复合年增长率增长，到 2030 年达到 39 亿美元。

反义疗法是用单链DNA寡核苷酸基因表现进行选择性和序列特异性抑制。它用于治疗肌萎缩侧索硬化症、亨廷顿病和阿兹海默症。另一方面， RNA干扰（RNAi）疗法由双链RNA（dsRNA）触发，并响应dsRNA而导致单链标靶RNA的序列特异性核糖核酸（mRNA）降解。 RNAi已被应用于治疗多种疾病，包括病毒感染、神经退化性疾病和某些癌症。

根据美国科学促进会 2023 年 7 月发表的一篇论文，麻省大学陈医学院和 RUSH 大学医学中心开发的一种反义疗法表明， X染色体脆折症候群被发现有助于恢復一种名为

遗传性疾病增加

遗传性疾病是由个体 DNA 异常引起的，这些疾病的传统治疗方法往往效果有限。反义和 RNAi 疗法透过在分子层面上针对这些疾病的潜在遗传原因提供了一种有前途的方法。此外，遗传病患病率的不断上升导致反义和 RNAi 疗法的临床试验和研究工作激增。成功的临床试验和监管核准进一步证明了这些治疗方法的潜力并支持市场成长。

基于 RNAi 的药物价格高成本

复杂的开发过程涉及先进技术和严格的监管要求，导致製造成本更高。这些成本通常反映在 RNAi 疗法的定价中，限制了患者和医疗保健系统对这些疗法的可及性。负担能力的挑战可能会阻碍普及并限制市场成长。结果，市场成长受到阻碍。

新药物传递的快速普及和 RNA 疗法的推出

先进药物递送技术的出现提高了反义和RNAi疗法的功效和标靶递送，促进了它们的普及。此外，基于RNA的药物的监管核准和成功进入市场增强了投资者的信心并活性化了研究和开发工作。这些技术进步和监管里程碑的融合正在创造一个有利的环境，推动反义和 RNAi 治疗市场的发展。

免疫反应

当外源性 RNA 分子（例如反义和 RNAi 疗法中使用的分子）被引入体内时，它们可以激活免疫系统。这可以触发先天免疫反应，包括发炎细胞激素的释放和免疫细胞的活化。身体的适应性免疫系统也有可能将外源性RNA辨识为威胁，导致产生针对治疗分子的抗体。

COVID-19 的影响

COVID-19 大流行对反义疗法和 RNAi 疗法市场产生了多种影响。一方面，对 mRNA 疫苗开发的关注加速了基于 RNA 的技术的接受度。然而，临床试验、供应链和研究活动的中断推迟了反义和 RNAi 疗法的开发和商业化。虽然人们对 RNA 技术的认识不断提高是一个积极的结果，但该行业在适应不断变化的环境方面面临着挑战​​，而韧性和适应性对于疫情后时代的持续成长至关重要。

RNA反义片段预计在预测期内是最大的

据估计，RNA 反义片段所占比重最大。这种创新的治疗方法旨在透过抑製或改变疾病相关蛋白质的产生来在基因层面上治疗疾病。 RNA反义技术预计将有多种应用，包括治疗遗传性疾病、癌症和病毒感染。 RNA反义具有精确干预基因表现的能力，是广泛市场中的重要组成部分，有助于开发针对各种病理的标靶化和个人化治疗解决方案。

预计癌症领域在预测期内复合年增长率最高

预计癌症领域在预测期内将出现良好的成长。反义疗法/RNAi疗法旨在选择性地靶向癌症相关基因并调节其表达，抑制肿瘤进展或促进癌细胞死亡。此部分包括多种方法，包括根据个人遗传特征量身定制的个人化 RNA 疗法。由于这些治疗方法具有针对性和精确性，因此它们有可能透过解决特定的生物学途径并提高治疗效果，同时最大限度地减少副作用来改变肿瘤学。

比最大的地区

由于研发投资的增加、慢性病盛行率的上升以及支持性的法规环境，亚太地区在预测期内占据了最大的市场占有率。中国、日本和印度等主要国家处于前沿，专注于基于RNA的新型治疗方法的开发和商业化。此外，随着个人化医疗意识的不断增强，本地和全球生物技术公司之间的合作研究正在推动进步。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。以美国为首，该地区在製药和生物技术研究上投入巨资，刺激了基于 RNA 的新型药物的研究和开发。有利的监管环境、行业相关人员之间的策略联盟以及慢性病的高盛行率正在促进市场扩张。此外，北美拥有完善的医疗基础设施、积极的个人化医疗方法以及强大的市场参与者。北美处于反义和 RNAi 疗法开发的前沿，使其成为全球市场上充满活力的重要参与者。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球反义疗法/RNAi疗法市场：途径分类

  • 皮下的
  • 静脉
  • 肺部输送
  • 蛛网膜下腔
  • 腹腔注射
  • 其他的

第六章 全球反义疗法/RNAi疗法市场：依适应症分类

  • 体染色体显性遗传疾病
  • 体染色体隐性遗传疾病
  • 染色体疾病
  • 其他的

第七章 全球反义疗法/RNAi 疗法市场：依技术分类

  • RNA反义
  • RNA干扰

第八章全球反义疗法/RNAi疗法市场：依应用分类

  • 眼科疾病
  • 呼吸系统疾病
  • 心臟代谢疾病/肾臟疾病
  • 癌症
  • 神经退化性疾病
  • 感染疾病
  • 遗传疾病
  • 皮肤病
  • 其他的

第9章全球反义疗法/RNAi疗法市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals（Akcea Therapeutics, Inc.）
  • Biogen Inc.
  • Sarepta Therapeutics, Inc.
  • Arbutus Biopharma
  • Silence Therapeutics
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Gene Signal International SA
  • Benitec Biopharma Ltd
  • Olix Pharmaceuticals
  • GSK plc
  • Sanofi
  • Bio-Path Holdings Inc
  • Antisense Therapeutics Limited.
  • Quark Pharmaceuticals
  • Merck
  • Astellas Pharma Inc
  • Marina Biosciences
  • Dicerna Pharmaceuticals
Product Code: SMRC25123

According to Stratistics MRC, the Global Antisense & RNAi Therapeutics Market is accounted for $1.66 billion in 2023 and is expected to reach $3.90 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It is used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. RNAi has applications in treating a wide range of conditions, including viral infections, neurodegenerative diseases, and certain cancers.

According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome.

Market Dynamics:

Driver:

Rising incidence of genetic disorders

Genetic disorders result from abnormalities in an individual's DNA, and traditional treatment options for these conditions are often limited. Antisense and RNA interference (RNAi) therapies offer a promising approach by targeting the underlying genetic causes of these disorders at the molecular level. Furthermore, the increasing prevalence of genetic disorders has prompted a surge in clinical trials and research efforts focusing on antisense and RNAi therapies. Successful trials and regulatory approvals further validate the potential of these treatments, driving market growth.

Restraint:

High cost of RNAi based drugs

The complex development process, involving advanced technologies and stringent regulatory requirements, contributes to elevated production costs. These expenses are often reflected in the pricing of RNAi therapeutics, limiting accessibility for patients and healthcare systems. Affordability challenges can impede widespread adoption, hindering the market's growth potential. As a result, it will hamper market growth.

Opportunity:

Rapid adoption of novel drug delivery and launch of RNA therapeutics

The advent of advanced drug delivery technologies has enhanced the efficacy and targeted delivery of antisense and RNA interference (RNAi) therapeutics, fostering their widespread adoption. Furthermore, the regulatory approval and successful market entry of RNA-based treatments have bolstered investor confidence and fuelled research and development initiatives. This convergence of technological advancements and regulatory milestones has created a favourable environment, propelling the Antisense & RNAi Therapeutics Market.

Threat:

Immune responses

When exogenous RNA molecules, such as those used in antisense and RNA interference (RNAi) therapies, are introduced into the body, they may activate the immune system. This can trigger innate immune responses, including the release of pro-inflammatory cytokines and the activation of immune cells. Also, the body's adaptive immune system may recognize the foreign RNA as a threat, leading to the production of antibodies against the therapeutic molecules.

Covid-19 Impact

The COVID-19 pandemic has had a mixed impact on the antisense and RNAi therapeutics markets. On one hand, the focus on mRNA vaccine development has accelerated RNA-based technology acceptance. However, disruptions in clinical trials, supply chains, and research activities have caused delays in the development and commercialization of anti-sense and RNAi therapies. While increased recognition of RNA technologies is a positive outcome, the industry faces challenges in adapting to the changing landscape, emphasising the importance of resilience and adaptability for continued growth in a post-pandemic era.

The RNA antisense segment is expected to be the largest during the forecast period

The RNA antisense segment is estimated to hold the largest share. This innovative therapeutic approach aims to treat diseases at the genetic level by inhibiting or modifying the production of disease-related proteins. RNA antisense technology holds promise for various applications, including treating genetic disorders, cancers, and viral infections. With its ability to precisely intervene in gene expression, RNA antisense represents a pivotal segment within the broader market, contributing to the development of targeted and personalised therapeutic solutions for a range of medical conditions.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is anticipated to have lucrative growth during the forecast period. Antisense and RNA interference (RNAi) therapies are designed to selectively target and modulate the expression of genes associated with cancer, inhibiting tumour progression or promoting cancer cell death. This segment encompasses a diverse range of approaches, including personalised RNA treatments tailored to individual genetic profiles. Because of their targeted and precise nature, these treatments have the potential to alter oncology by tackling certain biological pathways and improving therapeutic efficacy while minimising side effects.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increased investment in research and development, the rising prevalence of chronic diseases, and a supportive regulatory environment. Key countries such as China, Japan, and India are at the forefront, with a focus on developing and commercialising novel RNA-based therapies. Furthermore, collaborations between local and global biotech firms, along with a growing awareness of personalised medicine, drive advancements.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region, lead by the US, has made significant expenditures in pharmaceutical and biotechnology research, which has stimulated the development of novel RNA-based medicines. Favourable regulatory landscapes, strategic collaborations between industry stakeholders and a high prevalence of chronic diseases contribute to market expansion. It also has a well-established healthcare infrastructure, a proactive approach to personalised medicine, and prominent market players. North America is at the forefront of the development of antisense and RNAi treatments, making it a dynamic and significant player in the worldwide market.

Key players in the market

Some of the key players in the Antisense & RNAi Therapeutics Market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Biogen Inc, Sarepta Therapeutics, Inc, Arbutus Biopharma, Silence Therapeutics, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc, Gene Signal International SA, Benitec Biopharma Ltd, Olix Pharmaceuticals, GSK plc, Sanofi, Bio-Path Holdings Inc, Antisense Therapeutics Limited., Quark Pharmaceuticals, Merck, Astellas Pharma Inc, Marina Biosciences and Dicerna Pharmaceuticals.

Key Developments:

In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche; to develop and market, zilebesiran, investigational ribonucleic acid interference (RNAi) therapeutic to treat hypertension

In March 2023, OliX Pharmaceuticals, Inc. dosed the first patient in a Phase 1 clinical trial of an investigational RNAi therapeutic designed to treat age-related macular degeneration (AMD)

Routes of Administration Covered:

  • Subcutaneous Route
  • Intravenous Route
  • Pulmonary Delivery
  • Intrathecal Route
  • Intraperitoneal Injection
  • Other Routes of Administration

Indications Covered:

  • Autosomal Dominant Disease
  • Autosomal Recessive Disease
  • Chromosomal Disease
  • Other Indications

Technologies Covered:

  • RNA Antisense
  • RNA Interference

Applications Covered:

  • Ocular Disorders
  • Respiratory Disorders
  • Cardio metabolic & Renal Disorders
  • Cancer
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Genetic Disorders
  • Skin Diseases
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antisense & RNAi Therapeutics Market, By Route of Administration

  • 5.1 Introduction
  • 5.2 Subcutaneous Route
  • 5.3 Intravenous Route
  • 5.4 Pulmonary Delivery
  • 5.5 Intrathecal Route
  • 5.6 Intraperitoneal Injection
  • 5.7 Other Routes of Administration

6 Global Antisense & RNAi Therapeutics Market, By Indication

  • 6.1 Introduction
  • 6.2 Autosomal Dominant Disease
  • 6.3 Autosomal Recessive Disease
  • 6.4 Chromosomal Disease
  • 6.5 Other Indications

7 Global Antisense & RNAi Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 RNA Antisense
  • 7.3 RNA Interference

8 Global Antisense & RNAi Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Ocular Disorders
  • 8.3 Respiratory Disorders
  • 8.4 Cardio metabolic & Renal Disorders
  • 8.5 Cancer
  • 8.6 Neurodegenerative Disorders
  • 8.7 Infectious Diseases
  • 8.8 Genetic Disorders
  • 8.9 Skin Diseases
  • 8.10 Other Applications

9 Global Antisense & RNAi Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Alnylam Pharmaceuticals, Inc.
  • 11.2 Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
  • 11.3 Biogen Inc.
  • 11.4 Sarepta Therapeutics, Inc.
  • 11.5 Arbutus Biopharma
  • 11.6 Silence Therapeutics
  • 11.7 Isarna Therapeutics GmbH
  • 11.8 Arrowhead Pharmaceuticals, Inc.
  • 11.9 Gene Signal International SA
  • 11.10 Benitec Biopharma Ltd
  • 11.11 Olix Pharmaceuticals
  • 11.12 GSK plc
  • 11.13 Sanofi
  • 11.14 Bio-Path Holdings Inc
  • 11.15 Antisense Therapeutics Limited.
  • 11.16 Quark Pharmaceuticals
  • 11.17 Merck
  • 11.18 Astellas Pharma Inc
  • 11.19 Marina Biosciences
  • 11.20 Dicerna Pharmaceuticals

List of Tables

  • Table 1 Global Antisense & RNAi Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 3 Global Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 4 Global Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 5 Global Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 6 Global Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 7 Global Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 8 Global Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 9 Global Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 10 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 11 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 12 Global Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 13 Global Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 14 Global Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 15 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 16 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 17 Global Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 19 Global Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 20 Global Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 21 Global Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 22 Global Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 23 Global Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 24 Global Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 25 Global Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 26 Global Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 North America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 29 North America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 30 North America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 31 North America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 32 North America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 33 North America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 34 North America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 35 North America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 36 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 37 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 38 North America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 39 North America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 40 North America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 41 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 42 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 43 North America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 44 North America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 45 North America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 46 North America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 47 North America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 48 North America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 49 North America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 50 North America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 51 North America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 52 North America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 53 Europe Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 55 Europe Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 56 Europe Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 57 Europe Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 58 Europe Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 59 Europe Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 60 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 61 Europe Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 62 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 63 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 64 Europe Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 65 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 66 Europe Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 67 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 68 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 69 Europe Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 70 Europe Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 71 Europe Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 72 Europe Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 73 Europe Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 74 Europe Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 75 Europe Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 76 Europe Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 77 Europe Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 78 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 79 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 81 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 82 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 83 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 84 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 85 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 86 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 87 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 88 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 89 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 90 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 91 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 92 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 93 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 94 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 95 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 96 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 97 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 98 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 99 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 100 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 101 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 102 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 103 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 104 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 105 South America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 107 South America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 108 South America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 109 South America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 110 South America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 111 South America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 112 South America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 113 South America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 114 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 115 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 116 South America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 117 South America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 118 South America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 119 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 120 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 121 South America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 122 South America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 123 South America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 124 South America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 125 South America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 126 South America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 127 South America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 128 South America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 129 South America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 130 South America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 131 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 133 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
  • Table 134 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
  • Table 135 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
  • Table 136 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
  • Table 137 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
  • Table 138 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
  • Table 139 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 140 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
  • Table 141 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
  • Table 142 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
  • Table 143 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 144 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 145 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
  • Table 146 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
  • Table 147 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 148 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
  • Table 149 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 150 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
  • Table 151 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 152 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 153 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 154 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
  • Table 155 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
  • Table 156 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)